RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value

$5.38+0.10 (+1.89%)

Close on Nov 12, 2026Market cap $223.77MP/E –Yield –

RxSight EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

RxSight has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RXST.

Revenue growth-13.2% · median 9.8%

Gross margin77.5% · median 73.6%

Operating margin-43.2% · median -3.3%

Net margin-36.8% · median -2.7%

Advertisement
300 × 250

See a number that looks wrong?